Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells

Cancer Research

Volumn 66, Issue 17, 2006, Pages 8598-8607

  Litvinov, Ivan V ^a,b   Vander Griend, Donald J ^b   Xu, Yi ^a   Antony, Lizamma ^a   Dalrymple, Susan L ^a   Isaacs, John T ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CALCIUM ION; INTERFERON; METRIBOLONE; NOTCH1 RECEPTOR;

ARTICLE; CARCINOGENESIS; CELL COMPOSITION; CELL DIFFERENTIATION; CELL GROWTH; CELL HETEROGENEITY; CELL IMMORTALIZATION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWNSTREAM PROCESSING; DRUG MECHANISM; EPITHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; STEM CELL; UPREGULATION; WESTERN BLOTTING;

CALCIUM; CELL DIFFERENTIATION; CELL DIVISION; CELLS, CULTURED; CULTURE MEDIA, SERUM-FREE; EPITHELIAL CELLS; GENE EXPRESSION REGULATION; HUMANS; MALE; METRIBOLONE; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEM CELLS;

EID: 33749019746     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-1228     Document Type: Article

References (50)

1. Isaacs JT, Coffey DS. Etiology and disease process of benign prostatic hyperplasia. Prostate 1989;Suppl 2:33-50.
2. Bonkhoff H, Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 1996;28: 98-106.
3. van Leenders G, Dijkman H, Hulsbergen-van de Kaa C, Ruiter D, Schalken J. Demonstration of intermediate cells during human prostate epithelial differentiation in situ and in vitro using triple-staining confocal scanning microscopy. Lab Invest 2000;80:1251-8.
4. Hudson DL, O'Hare M, Watt FM, Masters JRW. Proliferative heterogeneity in the human prostate: evidence for epithelial stem cells. Lab Invest 2000;80: 1243.
5. Wang Y, Hayward SW, Cao M, Thayer KA, Cunha GR. Cell differentiation lineage in the prostate. Differentiation 2001;68:270-9.
6. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on α(2)β(1)-integrin expression. J Cell Sci 2001;114:3865-72.
7. Rumpold H, Heinrich E, Untergasser G, et al. Neuroendocrine differentiation of human prostatic primary epithelial cells in vitro. Prostate 2002;53:101-8.
8. Tsujimura A, Koikawa Y, Salm S, et al. Proximal location of mouse prostate epithelial stem cells: a model of prostatic homeostasis. J Cell Biol 2002;157: 1257-65.
9. Litvinov IV, De Marzo AM, Isaacs JT. Is the Achilles' heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003;88:2972-82.
10. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004;117: 3539-45.
11. Huss WJ, Gray DR, Greenberg NM, Mohler JL, Smith GJ. Breast cancer resistance protein-mediated efflux of androgen in putative benign and malignant prostate stem cells. Cancer Res 2005;65:6640-50.
12. Kurita T, Wang YZ, Donjacour AA, et al. Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system. Cell Death Differ 2001; 8:192-200.
13. Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the prostate. Development 2004;131: 4955-64.
14. Signoretti S, Pires MM, Lindauer M, et al. p63 regulates commitment to the prostate cell lineage. Proc Natl Acad Sci U S A 2005;102:11355-60.
15. Uzgare AR, Xu Y, Isaacs JT. In vitro culturing and characteristics of transit-amplifying epithelial cells from human prostate tissue. J Cell Biochem 2004;91:196-205.
16. Garraway LA, Lin D, Signoretti S, et al. Intermediate basal cells of the prostate: in vitro and in vivo characterization. Prostate 2003;55:206-18.
17. Tran CP, Lin C, Yamashiro J, Reiter RE. Prostate stem cell antigen is a marker of late intermediate prostate epithelial cells. Mol Cancer Res 2002;1:113-21.
18. Dalrymple S, Antony L, Xu Y, et al. Role of Notch-1 and E-cadherin in the differential response to calcium in culturing normal versus malignant prostate cells. Cancer Res 2005;65:9269-79.
19. van Leenders GJ, Gage WR, Hicks JL, et al. Intermediate cells in human prostate epithelium are enriched in proliferative inflammatory atrophy. Am J Pathol 2003;162:1529-37.
20. Masai M, Sumiya H, Akimoto S, et al. Immunohistochemical study of androgen receptor in benign hyperplastic and cancerous human prostates. Prostate 1990;17:293-300.
21. Prins GS, Birch L, Greene GL. Androgen receptor localization in different cell types of the adult rat prostate. Endocrinology 1991;129:3187-99.
22. Bonkhoff H, Stein U, Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate 1994;24:114-8.
23. Kyprianou N, Isaacs JT. Quantal relationship between prostatic dihydrotestosterone and prostatic cell content critical threshold concept. Prostate 1987;11:41-50.
24. Weijerman PC, Konig JJ, Wong ST, Niesters HG, Peehl DM. Lipofection-mediated immortalization of human prostatic epithelial cells of normal and malignant origin using human papillomavirus type 18 DNA. Cancer Res 1994;54:5579-83.
25. Bello D, Webber MM, Heinman HK, Wartinger DD, Rhim JS. Androgen responsive adult human prostatic epithelial cell lines immortalized by human papillomavirus 18. Carcinogenesis 1997;18:1215-23.
26. Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B, Hhim JS. A novel human cell culture model for the study of familial prostate cancer. Cancer Res 2001; 61:5969-73.
27. Denmeade SR, Sokoll LJ, Dalrymple S, et al. Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. Prostate 2003;54: 249-57.
28. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22RvI. In Vitro Cell Dev Biol Anim 1999;35:403-9.
29. Lee YG, Korenchuk S, Lehr J, Whitney S, Vessela R, Pienta KJ. Establishment and characterization of a new human prostatic cancer cell line: DuCaP. In Vivo 2001; 15:157-62.
30. Korenchuk S, Lehr JE, McClean L, et al. VCaP, a cell-based model system of human prostate cancer. In Vivo 2001;15:163-8.
31. Koochekpour S, Maresh GA, Katner A, et al. Establishment and characterization of a primary androgen-responsive African-American prostate cancer cell line, E006AA. Prostate 2004;60:141-52.
32. Kemppainen JA, Lane MV, Sar M, Wilson EM. Androgen receptor phosphorylation, turnover, nuclear transport, and transcriptional activation. J Biol Chem 1992;267:968-74.
33. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development Am J Pathol 2000;157:1769-75.
34. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with trans-activating, death-inducing, and dominant-negative activities. Mol Cell 1998;3:305-16.
35. Grayhack JT, Sensibar JA, Ibo KY, Kasjanski RZ, Kozlowski JM, Lee C. Synergistic action of steroids and spermatocele fluid on in vitro proliferation of prostate stroma. J Urol 1998;159:2202-9.
36. Basrawala Z, Alimirah F, Xin H, et al. Androgen receptor levels are increased by interferons in human prostate stromal and epithelial cells. Oncogene 2005;25:2812-7.
37. Webber MM, Bello D, Kleinman HK, Hoffman MP. Acinar differentiation by non-malignant immortalized human prostatic epithelial cells and its loss by malignant cells. Carcinogenesis 1997;18:1225-31.
38. 1 integrin regulate acinar morphogenesis of normal and malignant human prostate epithelial cells. Prostate 2001;46:142-53.
39. Iso T, Kedes L, Hamamori Y. HES and HEKP families: multiple effectors of the Notch signaling pathway. J Cell Physiol 2003;194:237-55.
40. Fischer A, Klattig J, Kneitz B, et al. Hey basic helix-loop-helix transcription factors are repressors of GATA4 and GATA6 and restrict expression of the GATA target gene ANF in fetal hearts. Mol Cell Biol 2005;25:8960-70.
41. Elagib KE, Xiao M, Hussaini IM, et al. Jun blockade of erythropoiesis: role for repression of GATA-1 by HERP2. Mol Cell Biol 2004;24:7779-94.
42. Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey-1, a mediator of Notch signaling, is an androgen receptor corepressor. Mol Cell Biol 2005;25:1425-36.
43. Perez-Stable CM, Pozas A, Roos BA. A role for GATA transcription factors in the androgen regulation of the prostate-specific antigen gene enhancer. Mol Cell Endocrinol 2000;167:43-53.
44. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterisation of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
45. Isaacs JT, Wake N, Coffey DS, Sandberg AA. Genetic instability coupled to clonal selection as a mechanism for tumor progression in the Dunning R-3327 rat prostatic adenocarcinoma system. Cancer Res 1982;42: 2353-71.
46. Cahill DP, Kinzler KW, Vogelstein B, Lengauer C. Genetic instability and Darwinian selection in tumours. Trends Cell Biol 1999;9:M57-60.
47. Wicha MS, Liu S, Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res 2006;66:1883.
48. Uzgare AR, Isaacs JT. Prostate cancer: potential targets of anti-proliferative and apoptotic signaling pathways. Int J Biochem Cell Biol 2005;37:707-14.
49. Laufer M, Denmeade SR, Sinibaldi VJ, Carducci MA, Eisenberger MA. Complete androgen blockade for prostate cancer: what went wrong? J Urol 2000;164:3-9.
50. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.